Cargando…
Cost-Effectiveness and Cost-Utility of Early Levodopa in Parkinson’s Disease
BACKGROUND: In the Levodopa in EArly Parkinson’s disease (LEAP) study, 445 patients were randomized to levodopa/carbidopa 100/25 mg three times per day for 80 weeks (early-start) or placebo for 40 weeks followed by levodopa/carbidopa 100/25 mg three times per day for 40 weeks (delayed-start). OBJECT...
Autores principales: | Verschuur, Constant V.M., Suwijn, Sven R., de Haan, Rob J., Boel, Judith A., Post, Bart, Bloem, Bas R., van Hilten, Johannes J., van Laar, Teus, Tissingh, Gerrit, Munts, Alexander, Dijkgraaf, Marcel G.W., de Bie, Rob M.A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661337/ https://www.ncbi.nlm.nih.gov/pubmed/35938258 http://dx.doi.org/10.3233/JPD-223247 |
Ejemplares similares
-
Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson’s disease: the LEAP-study
por: Verschuur, Constant V. M., et al.
Publicado: (2015) -
The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review
por: Suwijn, Sven R, et al.
Publicado: (2015) -
SERT-to-DAT ratios in early Parkinson’s disease do not correlate with the development of dyskinesias
por: Suwijn, Sven R, et al.
Publicado: (2013) -
Predictors of Time to Discontinuation of Levodopa-Carbidopa Intestinal Gel Infusion: A Retrospective Cohort Study
por: Moes, Harmen R., et al.
Publicado: (2020) -
Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24 months follow‐up
por: van Mierlo, Tom J. M., et al.
Publicado: (2021)